MaRS Innovation has announced the launch of a fifth project to be developed under the BRIDGE LAB150, a partnership between Evotec SE and MaRS Innovation. The aim of the project is to develop a novel rapid-acting antidepressant with the potential to provide patient relief much faster than conventional treatments. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/new-lab150-project-identified-5820